Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Friday 22 February, 2019

GlaxoSmithKline PLC

GSK response to SFO Statement

RNS Number : 8883Q
GlaxoSmithKline PLC
22 February 2019


Issued: 22 February 2019, London UK - LSE Announcement


GSK response to SFO Statement



In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.


About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit



GSK enquiries:

UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502


Tim Foley

+44 (0) 20 8047 5502


Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 208 047 5194


Jeff McLaughlin

+1 215 751 7002



Cautionary statements regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.






Registered in England & Wales:

No. 3888792



Registered Office:

980 Great West Road

Brentford, Middlesex




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t